resTORbio (NASDAQ:TORC) reported new data from its Phase 2b trial of RTB101 for the treatment of respiratory tract infections (RTIs) in patients 65 years of age and older.
Licensed from Novartis, RTB101 is a TORC1 inhibitor. TORC1 inhibition is believed to enhance immune function and reduce infection, as well as offer therapeutic benefits in multiple aging-related conditions.
The new data demonstrate that a daily 10 mg dose of RTB101 reduced the rate of laboratory-confirmed RTIs by nearly 79%, compared with placebo, among participants with asthma.
“Viral RTIs are one of the most common causes of asthma exacerbations, and there is a large unmet medical need for antiviral therapies that decrease the incidence of RTIs, particularly in older asthmatics in whom asthma exacerbations are associated with high rates of morbidity and mortality,” Dr. Joan Mannick, resTORbio’s co-founder and CMO, said in a statement.
resTORbio recently initiated a Phase 3 trial for RTB101 and plans to initiate a second Phase 3 trial in the fourth quarter of 2019. The company expects top-line data from both trials in mid-2020.
